The FDA has approved Merck's (MRK -0.2%) Liptruzet drug for treating elevated LDL cholesterol...

The FDA has approved Merck's (MRK -0.2%) Liptruzet drug for treating elevated LDL cholesterol levels in patients with primary or mixed hyperlipidemia. Lipruzet combines two existing anti-cholesterol drugs, ezetimibe and atorvastatin. It'll be available to wholesalers next week. (PR)

From other sites
Comments (3)
  • bricius
    , contributor
    Comments (52) | Send Message
    Can somebody help? What is the sales projection for this Vytorin-like combo? I have the impression this approval will help Merck bottom line a bit while facing the patent cliff, but no way it's going to be a game changer.
    3 May 2013, 05:42 PM Reply Like
  • Alvingolub
    , contributor
    Comments (257) | Send Message
    Many doctors are writing for Zetia and generic Lipitor. The new approved combination will not be much more profitable. It will add to their profits somewhat because every approval is valuable, but not a dream of a game changer. Every investor should have some drug stocks and Merck might be the best. It is like investing in Exxon. $25 is a high paying bond and $20 is a very speculative bio tech, which I think will do very well. I could be wrong.


    4 May 2013, 11:37 PM Reply Like
  • 5967241
    , contributor
    Comments (107) | Send Message
    Market knows that there is a better drug in Vascepa and Anchor by end of the year which will occupy this market completely.
    Lipruzet approval from FDA was not convincing for many. In any case, it is wont bring in anything for MERCK and market reacting in the right manner.
    6 May 2013, 02:24 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs